Skip to main content

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis

The Original Article was published on 28 April 2021

Correction to: Cardiovasc Diabetol (2021) 20:91 https://doi.org/10.1186/s12933-021-01276-9

Following publication of the original article [1], the authors regret the errors of the original data display in the forest plots, which has been corrected with this erratum.

For the analysis of amputation, in DAPA-CKD study, there should be 35 amputation events out of 2149 total events in SGLT2i treatment arm, and 39 amputation events out of 2149 total events in control treatment arm. And in DELIGHT study, there should be 1 amputation event out of 145 total events in SGLT2i treatment arm.

For the analysis of PAD and DF, there should be 573 total events in SGLT2i treatment arm in DEPICT-1 study, and there should be 419 total events in SGLT2i treatment arm in EMPA Barnett 2014, according to the data from Clinicaltrial.gov.

The data has been updated with in the new Fig. 1a and Fig. 1b. Some results from the sensitivity analyses were slightly changed and have been also updated in the new Table 1. The results of meta-regression remained unchanged in current reserved decimal digits. Such mild changes did not cause any substantial influence to the conclusion and clinical significance of our study.

Fig. 1
figure1

The risk of amputation and PAD in patients with SGLT2i treatment. a The risk of amputation in patients with SGLT2i treatment. b The risk of PAD in patients with SGLT2i treatment. PAD peripheral arterial disease, SGLT2i sodium glucose co-transporter 2 inhibitor

Table 1 Risk of amputation, PAD and DF events in patients with SGLT2i treatment

The contents in the abstract and main text have also been updated. All revisions are highlighted in bold fonts as follows.

In the result section of the abstract, the revision is shown as “The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,765/33,406, 36,701/28,676 and 32,043/25,558 respectively”.

In the Included studies section of the main text, the revision is shown as “The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,765/33,406, 36,701/28,676 and 32,043/25,558 respectively”.

In the Risk of amputation, PAD and DF in patients with SGLT2i treatment section of the main text, the revisions are shown as: (1) “Compared with non-SGLT2i users, the risk of amputation (OR = 1.21, 95% CI 1.06 to 1.37, P = 0.004) (Fig. 1a) ……”; (2) “As for study population, the incidence of amputation (OR = 1.24, 95% CI 1.08 to 1.42, P = 0.002) and PAD (OR = 1.22, 95% CI 1.03 to 1.45, P = 0.02) were significantly increased in SGLT2i users versus non-SGLT2i users……”; (3) “Moreover, the risk of amputation (OR = 1.20, 95% CI 1.05 to 1.36, P = 0.006) and the risk of PAD (OR = 1.22, 95% CI 1.03 to 1.44, P = 0.02) were significantly higher in RCTs with study duration longer than 52 weeks……”.

Reference

  1. 1.

    Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, Ji L. SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol. 2021;20(1):91. https://doi.org/10.1186/s12933-021-01276-9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Xiaoling Cai or Linong Ji.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lin, C., Zhu, X., Cai, X. et al. Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 20, 119 (2021). https://doi.org/10.1186/s12933-021-01306-6

Download citation